A Rong, Han Zhaoguo, Wang Tianyi, Zhu Mengyuan, Zhou Meifang, Sun Xilin
Department of Nuclear Medicine, The Fourth Hospital of Harbin Medical University, Harbin, China.
NHC Key Laboratory of Molecular Probe and Targeted Diagnosis and Therapy, Molecular Imaging Research Center (MIRC) of Harbin Medical University, Harbin, China.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Jan-Feb;16(1):e1933. doi: 10.1002/wnan.1933. Epub 2023 Oct 19.
Although our understanding of lung cancer has significantly improved in the past decade, it is still a disease with a high incidence and mortality rate. The key reason is that the efficacy of the therapeutic drugs is limited, mainly due to insufficient doses of drugs delivered to the lungs. To achieve precise lung cancer diagnosis and treatment, nano-particles (NPs) pulmonary delivery techniques have attracted much attention and facilitate the exploration of the potential of those in inhalable NPs targeting tumor lesions. Since the therapeutic research focusing on pulmonary delivery NPs has rapidly developed and evolved substantially, this review will mainly discuss the current developments of pulmonary delivery NPs for precision lung cancer diagnosis and therapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > In Vivo Nanodiagnostics and Imaging.
尽管在过去十年中我们对肺癌的认识有了显著提高,但它仍然是一种发病率和死亡率很高的疾病。关键原因是治疗药物的疗效有限,主要是因为输送到肺部的药物剂量不足。为了实现肺癌的精确诊断和治疗,纳米颗粒(NPs)肺部给药技术备受关注,并有助于探索可吸入NPs靶向肿瘤病变的潜力。由于专注于肺部给药NPs的治疗研究迅速发展且有了实质性的演变,本综述将主要讨论用于精确肺癌诊断和治疗的肺部给药NPs的当前进展。本文分类如下:治疗方法与药物发现>呼吸系统疾病的纳米医学;治疗方法与药物发现>新兴技术;诊断工具>体内纳米诊断与成像。